BridgeBio Pharma BBIO 深 沪
等待开盘 11-26 09:30:00 美东时间
70.63
-0.360
-0.51%
华盛通- 最 高71.65
- 今 开70.675
- 成交量 187.71万股
- 最 低 69.53
- 昨 收 70.99
- 总市值 134.90亿
- 52周最高 71.65
- 市盈率 静 --
- 换手率 0.98%
- 52周最低 25.34
- 委 比 -45.66%
- 总股本 1.91亿
- 历史最高 73.50
- 量 比 0.67
- 振 幅 2.99%
- 历史最低 4.98
- 每 手 1
- 风险率 10.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
11-25 22:08
BridgeBio to Participate in December Investor Conferences
BridgeBio Pharma, Inc. announced that its management team will participate in fireside chats at two upcoming healthcare investor conferences: the Piper Sandler Healthcare Conference in New York on December 2 at 10:30 am EST and the Evercore ISI HealthCONx Conference in Miami on December 3 at 3:00 pm EST. Live webcasts of these presentations can be accessed via BridgeBio's website, and replays will be available for 90 days. The company specializes...
11-25 12:30
美股盘后 | Symbotic Inc. - Class A Common Stock涨15.58%，Keysight Technologies涨14.08%
Symbotic Inc. - Class A Common Stock涨15.58%；Keysight Technologies涨14.08%；伍德沃德涨8.74%
11-25 07:12
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma announced on November 17, 2025, that its compensation committee approved equity grants totaling 34,199 restricted stock units (RSUs) to 12 new employees. The RSUs will vest quarterly over a specified period, with one-fourth vesting on November 16, 2026, and the remainder vesting in equal quarterly installments thereafter, contingent on continued employment. These awards were made under the company’s Amended and Restated 2019 Indu...
11-19 21:01
BridgeBio Oncology Therapeutics Reports Q3 2025 Progress
Bridgebio Oncology Therapeutics, Inc. ( ($BBOT) ) has released its Q3 earnings....
11-19 12:05
BBOT to Participate in Upcoming December Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (BBOT) announced that its leadership team will participate in two investor conferences in December. The first presentation will be at the Piper Sandler 37th Annual Healthcare Conference on December 2 at 2:00 p.m. ET, and the second at the 8th Annual Evercore Healthcare Conference on December 3 at 9:35 a.m. ET. Live webcasts and replays will be available on BBOT’s website. BBOT focuses on advancing novel therapies t...
11-18 21:05
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
BBOT, a clinical-stage biopharma company focused on RAS and PI3Kα pathway malignancies, reported Q3 2025 financials with $468.3M cash runway, advancing three Phase 1 KRAS and PI3Kα inhibitors.近的数据读出预计2026年，任命新任CFO。季度R&D费用达到3510万美元，管理费用为1410万美元，总净亏损4470万美元。
11-12 21:05
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
